Evaluation of CPK (Creatinine Phosphokinase) in Hypertensive Patients used either Statin and/or Ezetimibe
Main Article Content
Keywords
CPK (Creatinine Phosphokinase), Rhabdomyolysis, Statin, Ezetimibe, Hypertension
Abstract
Background: The effectiveness of cholesterol in the improvement of cardiovascular disorder used to be proven in the 2d half of of the twentieth century. Cholesterol researcher Daniel Steinberg writes that whilst the 1984 Primary Coronary Prevention Study confirmed that reducing ldl cholesterol substantially reduces the chance of coronary heart assault and angina, clinicians, consisting of cardiologists, mostly disagree. Not convinced. In the 1990s, after a public marketing campaign in the United States to instruct human beings about ldl cholesterol ranges and the distinction between HDL and LDL cholesterol, countless pharmaceutical businesses started out producing their personal statins. Ezetimibe is a drug used to deal with excessive blood ldl cholesterol and some different lipid disorders. It is frequently used with dietary adjustments and statins. It's now not as famous as statins.
Aim: To reflect the serous side effect of combination of both Ezetimibe and Statin in elevation of CPK.
Patients and Methods: In this study, patients (50-75) will be divided into three organizations:
1-The first group which were treated only by Statin which were (145) patients
2-Second group which were treated by Ezetimibe were (140) Patients.
3-The third group who treated by both Statin and Ezetimibe were (142) Patients.
4- The total number were (427).
All the patients which were investigated regularly by each of their visit and, lab measurement of serum PCK in each visit. And all the patients were followed and also each patient received Statin, Ezetimibe or both of these drugs for 3 months and during these three months they followed and investigated completely.
Results: We found 145 patients (33.94%) responded to simvastatin 40mg/day when compared to those patients who treated by Ezetimibe 10mg/day which were 140(32.75%), While 142(33.25%) patients had good response when treated by combination of both Simvastatin and Ezetimibe Simvastatin10mg/ day, and statin 10mg/day. And 67(15.70%), complained from Rhabdomyolysis, in those patients treated by Ezetimibe 10mg/day. While 105(24.60%), were complained from Rhabdomyolysis, in those patients treated by a combination of both Ezetimibe 10mg/ day, and statin 10mg/day. We conclude from this study that; although there is significant effect of Statin and Ezetimibe in lowering Serum Lipids in general, but there is a serious increase of CPK which lead to Rhabdomyolysis, especially when moderately high doses of combination were used
References
172. doi:10.1016/j.cell.2015.01.036. PMC 4525717. PMID 25815993.
2. Steinberg D (2007). The cholesterol wars: the skeptics vs. the preponderance of evidence. Academic Press. pp. 6–9. ISBN 978-0-12-373979-7.
3. Endo A (2010). "A historical perspective on the discovery of statins". Proceedings of the Japan Academy. Series B, Physical and Biological
Sciences. 86 (5): 484–93. Bibcode:2010PJAB...86..484E. doi:10.2183/pjab.86.484. PMC 3108295. PMID 20467214.
4. Simons J (January 2003). "The $10 billion pill". Fortune. 147 (1): 58–62, 66, and 68. PMID 12602122.
5. Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH (1976). "Crystal and molecular structure of compactin, a new antifungal
metabolite from Penicillium brevicompactum". Journal of the Chemical Society, Perkin Transactions 1 (11): 1165–70. doi:10.1039/P19760001165. PMID 945291.
6. Scandinavian Simvastatin Survival Study Group (November 1994). "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)". Lancet. 344 (8934): 1383–89. doi:10.1016/S0140-6736(94)90566-5. PMID 7968073. S2CID 5965882.
7. "Ezetimibe Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 13 April 2019.
8. U.S. National Library of Medicine, National Institutes of Health, U.S. Department of Health and Human Services. Page last updated: 27
October 2014 Medline Plus: Ezetimibe.
9. "Cholesterol Drugs". American Heart Association. Retrieved 24 December 2019.
10. ABD TT, Jacobson TA (May 2011). "Statininduced myopathy: a review and update". Expert Opinion on Drug Safety. 10 (3): 373–87. doi:10.1517/14740338.2011.540568. PMID21342078. S2CID 207487287
11. Naci H, Brugts J, Ades T (July 2013). "Comparative tolerability and harms of individual statins: a study-level network metaanalysis of 246955 participants from 135 randomized, controlled trials" (PDF). Circulation: Cardiovascular Quality and Outcomes. 6 (4): 390–99. doi:10.1161/CIRCOUTCOMES.111.000071.PMID 23838105. S2CID 18340552.
12. Bellosta S, Corsini A (November 2012). "Statin drug interactions and related adverse reactions". Expert Opinion on Drug
Safety. 11 (6): 933–46. doi:10.1517/14740338.2012.712959. PMID22866966. S2CID 6247572
13. S.D. Lahiri, P.F. Wang, P.C. Babbitt, M.J. McLeish, G.L. Kenyon, K.N. Allen, The 2.1 Å Structure of Torpedo californica creatine kinase
complexed with the ADP–Mg2+–NO3−–creatine transition-state analogue complex. Biochemistry, 41,(2002), 13861– 13867.
14. R. Grosse, E. Spitzer, V.V. Kupriyanov, V.A. Saks, K.R. Repke, Coordinate interplay between (Na2+ K+)-ATPase and creatine phosphokinase
optimizes (Na+/K+)-antiport across the membrane of vesicles formed from the plasma membrane of cardiac muscle cell. Biochim. Biophys. Acta, 603, (1980), 142– 156.
15. P. Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician. 2002; 65:907–9.
16. 16-Baeza-Trinidad (2015) Intern Med J 45(11): 1173-8 +PMID: 26010490 [PubMed]
17. McMahon (2013) JAMA Intern Med 173(19):1821-8 +PMID: 24000014 [PubMed]
18. Sauret JM, Marinides G, Wang GK (March 2002). "Rhabdomyolysis". American Family Physician. 65 (5): 907–12. PMID 11898964.
19. Sathasivam S, Lecky B (November 2008). "Statin induced myopathy". BMJ. 337:a2286. doi:10.1136/bmj.a2286. PMID 18988647
. S2CID 3239804.
20. Huerta-Alardín AL, Varon J, Marik PE (April 2005). "Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians". Critical Care. 9 (2): 158–69. doi:10.1186/cc2978. PMC 1175909. PMID 15774072.
21. Warren JD, Blumbergs PC, Thompson PD (March 2002). "Rhabdomyolysis: a review". Muscle & Nerve. 25 (3): 332–47. doi:10.1002/mus.10053. PMID 11870710. S2CID 8731940.
22. Knochel JP. Rhabdomyolysis and myoglobinuria. Annu Rev Med 1982; 33:435.
23. Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med 2007; 18:90.
24. Fadia Tohme Shaya , Krystal Sing , Robert Milam , Fasahath Husain, Michael A Del Aguila , Miraj Y Patel (Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses” Am J Cardiovasc Drug. 2020 Jun;20(3):239-248. doi: 10.1007/s40256-019-00379-9.
25. Patel J, Sheehan V, Gurk-Turner C. Ezetimibe (Zetia): a new type of lipid-lowering agent. Proc (Bayl Univ Med Cent). 2003 Jul;16(3):354-
8. [PMC free article] [PubMed] [Reference list].
26. Samia Mora and Paul M Ridker; “Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi:
10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1.
27. Takamitsu Nakamura, Mitsumasa Hirano, Yoshinobu Kitta, Daisuke Fujioka, YukioSaito, Ken-ichi Kawabata, Jun ei Obata, Yosuke
Watanabe, KazuhiroWatanabe, Kiyotaka Kugiyama,, “A comparison of the efficacy of combined ezetimibe and statin therapy with
doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy”, Journal of Cardiology, Volume 60, Issue 1, July
2012, Pages 12-17.
28. https://doi.org/10.1016/j.jjcc.2012.02.005
29. Noemie Chanson, Philippe Bossi, Luminita Schneider, Edward Bourry, and Hassane Izzedine “Rhabdomyolysis after ezetimibe/simvastatin therapy in an HIV-infected patient” NDT Plus. 2008 Jun; 1(3): 157–161. doi: 10.1093/ndtplus/sfn012
30. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, et al. “Safety and Associated Adverse Events: A Scientific
Statement From the American Heart Association" (2019).
31. "Ezetimibe - National Library of Medicine HSDB Database". Toxnet.nlm.nih.gov. National Library of Medicine. Retrieved 29 May 2018.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.